See more : Sudarshan Chemical Industries Limited (SUDARSCHEM.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Impel Pharmaceuticals Inc. (IMPL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Impel Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Bangkok Dusit Medical Services Public Company Limited (BDMS-R.BK) Income Statement Analysis – Financial Results
- Brookfield Infrastructure Corporation (BIPC) Income Statement Analysis – Financial Results
- PI Industries Limited (PIIND.BO) Income Statement Analysis – Financial Results
- KludeIn I Acquisition Corp. (INKAU) Income Statement Analysis – Financial Results
- Jamna Auto Industries Limited (JAMNAAUTO.NS) Income Statement Analysis – Financial Results
Impel Pharmaceuticals Inc. (IMPL)
About Impel Pharmaceuticals Inc.
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 12.65M | 668.00K | 0.00 | 0.00 |
| Cost of Revenue | 6.50M | 691.00K | 0.00 | 0.00 |
| Gross Profit | 6.16M | -23.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 48.66% | -3.44% | 0.00% | 0.00% |
| Research & Development | 11.46M | 20.56M | 27.29M | 28.81M |
| General & Administrative | 77.89M | 50.90M | 18.05M | 12.75M |
| Selling & Marketing | 7.60M | 12.60M | 0.00 | 0.00 |
| SG&A | 77.89M | 50.90M | 18.05M | 12.75M |
| Other Expenses | -9.29M | -5.05M | -408.00K | -680.00K |
| Operating Expenses | 89.34M | 71.46M | 45.33M | 41.57M |
| Cost & Expenses | 95.84M | 72.15M | 45.33M | 41.57M |
| Interest Income | 10.58M | 2.25M | 0.00 | 417.00K |
| Interest Expense | 13.84M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.20M | 1.09M | 1.08M | 722.00K |
| EBITDA | -83.18M | -70.40M | -44.26M | -40.84M |
| EBITDA Ratio | -657.48% | -10,701.50% | 0.00% | 0.00% |
| Operating Income | -83.18M | -71.49M | -45.33M | -41.57M |
| Operating Income Ratio | -657.48% | -10,701.50% | 0.00% | 0.00% |
| Total Other Income/Expenses | -23.13M | -5.05M | -463.00K | -263.00K |
| Income Before Tax | -106.31M | -76.53M | -45.80M | -41.83M |
| Income Before Tax Ratio | -840.28% | -11,457.19% | 0.00% | 0.00% |
| Income Tax Expense | 23.13M | 2.00K | 1.00K | 30.00K |
| Net Income | -129.44M | -76.54M | -45.80M | -41.86M |
| Net Income Ratio | -1,023.08% | -11,457.49% | 0.00% | 0.00% |
| EPS | -5.52 | -5.24 | -3.49 | -3.19 |
| EPS Diluted | -5.52 | -5.24 | -3.49 | -3.19 |
| Weighted Avg Shares Out | 23.45M | 14.60M | 13.14M | 13.14M |
| Weighted Avg Shares Out (Dil) | 23.45M | 14.60M | 13.14M | 13.14M |
Impel NeuroPharma, Inc. (IMPL) CEO Adrian Adams on Q4 2021 Results - Earnings Call Transcript
Impel NeuroPharma to Present Trudhesa™ Data at 2022 Scientific Meeting of American Academy of Neurology
Impel NeuroPharma to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022
Impel NeuroPharma to Participate in Upcoming Virtual Investor Conferences
Impel NeuroPharma, Inc. (IMPL) CEO Adrian Adams on Q3 2021 Results - Earnings Call Transcript
Carepoint Pharmacy Selected by Impel NeuroPharma as a Digital Pharmacy Partner for the Launch of Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray for the Acute Treatment of Migraine
Why Impel NeuroPharma Dived by 24% Today
Impel NeuroPharma To Raise $45M Via Equity Offering
Impel NeuroPharma Announces Pricing of $45.0 Million Public Offering
Why Impel NeuroPharma Stock Blasted 27% Higher Thursday
Source: https://incomestatements.info
Category: Stock Reports